Taylor Wessing’s Post

Our team at Lowenstein Sandler LLP advised on the private placement of $100M common stock of Context Therapeutics for Piper Sandler. Read more about this transaction and our role in the process. #corporatelaw #lawfirms #securitieslaw #capitalmarkets #lawyers

A good read on IPO trends. Some highlights: - Most are clinical stage and they tend to outperform preclinical IPOs - private and public investors place a majority of value on the lead asset - financing rounds have been large to ensure generating clinical data, rather through multiple smaller rounds - recent IPOs that have gone public have a step-up from their last private financing of around 1.2x https://lnkd.in/e-jRetmy #IPO #biotech #strategy

WSB Investor Call | June 21, 2022 (Preview) Here's a preview of the investor call with David Maris and Sarepta Therapeutics CEO Douglas S. Ingram. Whether you own $SRPT or thinking of getting long, you can't miss this discussion. "Our goal here is to delve deeper into the implications of the approval and understand Sarepta's longer term objectives." - David Maris "This is an enormous moment for the company." - Doug Ingram Access the entire Investor Call on $SRPT and don't miss Doug's incredible insights near the end on the importance of corporate culture in his organizations. Click the link in the comments sections to access. Fantastic discussion gentlemen! #InvestSmarter

Agile Therapeutics ($AGRX) *** “At least $25M” *** Strong Words yet 2-months later Agile Therapeutics announces the $25M won’t (didn’t) happen I wonder what could have changed in 6-weeks to derail their “at least” expectation 🤔 In addition: Key Nasdaq Compliance Dates March 25th: Shareholder Equity April 2nd: $1 Minimum Bid* * After two significant Reverse Splits (RS) I do not believe (not 100% sure) Agile Therapeutics is eligible for another RS. Looks like OTC land is inbound All of this with the same leadership team (Definition of insanity?) and BOD (Is the BOD really looking out for Shareholders?). So much lost potential 😞 Troop Matt Riley Joshua Brown Gross Law Firm, P.C. Robbins LLP Johnson Fistel, LLP

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA 3/2024”. 📈 As of the end of March 2024 we identified the following current VC trends in the United States: - Total Healthcare & Life Sciences funding reached EUR 8,217m - Biotech received 61% of the total investment volume (EUR 5,037m) with oncology being the leading indication (31%) - In March Mirador Therapeutics secures the highest transaction volume with EUR 368m, followed by Alumis with EUR 240m and Avenzo Therapeutics with EUR 205m - Premji Invest - US (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and Novo Holdings (Denmark) To access the full report, please click:  https://lnkd.in/d-ejFZWz #capital #biotech #venturecapital #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets #valuation #mergers #oncology

Thoughts on this? >> As the biotech markets warm up, signs point to crossover rounds returning >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #biotech #healthcare #pharma

To learn something from the past, it is probably more insightful to look at the graveyard rather than the survivors, as pointed out in Nicholas Taleb's Black Swan.  Here's a nice snapshot of recent biotech acquisitions that didn't exactly go as planned. Do you see a pattern? https://lnkd.in/g8hWdcGU #biotechology

Shedding the "dirty word" connotation: I wrote about the appetite for biotech crossover rounds this morning for Endpoints News, just as two of the drug development industry's largest private financings of 2024 were announced (Alumis' $259 million and Sionna's $182 million). #crossover #biotech #drugdevelopment #lifesciencesindustry #biotechindustry #pharma #venturecapital #publicmarkets #ipo

Thoughts on this? >> Moderna partners with Blackstone on flu shots, nabbing up to $750M in R&D funding >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare

Thoughts on this? >> As the biotech markets warm up, signs point to crossover rounds returning >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech